Research programme: immunotherapeutic vaccines - Scancell

Drug Profile

Research programme: immunotherapeutic vaccines - Scancell

Alternative Names: Modi-1; PAP vaccine - Scancell; PAP-114; SCIB-2; SCMod 1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scancell
  • Developer Karolinska Institute; Scancell
  • Class Cancer vaccines; DNA vaccines; Peptide vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Rheumatoid arthritis
  • No development reported Cancer
  • Discontinued Infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 13 Sep 2017 Scancell announces intention to submit clinical trial application in United Kingdom for Breast cancer, Ovarian cancer and Sarcoma in 2018
  • 06 Sep 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top